New study aims to prevent hepatitis c in kidney transplant patients
NCT ID NCT05653232
First seen Feb 18, 2026
Summary
This study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. Participants are split into two groups: one starts the medication just before transplant and takes it for only 2 weeks, while the other starts after transplant and takes it for 12 weeks. The goal is to see which approach better prevents HCV infection and liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Loma Linda University Health
RECRUITINGLoma Linda, California, 92408, United States
Contact Email: •••••@•••••
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
-
University of California San Diego
RECRUITINGLa Jolla, California, 92037, United States
Contact Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Email: •••••@•••••
Contact
-
University of Utah Medical Center
RECRUITINGSalt Lake City, Utah, 84132, United States
Contact Email: •••••@•••••
Contact
-
University of Wisconsin, Madison
TERMINATEDMadison, Wisconsin, 53792, United States
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sofosbuvir/Velpatasvir (SOF/VEL)
What this could lead to
If successful, this could show that starting HCV medication before transplant with a shorter course is safe and effective, potentially simplifying treatment and reducing costs.
What could go wrong
This is a relatively small, early-stage trial (120 participants) comparing two timing strategies, so results may not apply broadly. There is a risk of HCV transmission or liver injury despite treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.